Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04568122 · ClinicalTrials.gov registry record · NA
Rapid Turnaround, Home-based Saliva Testing for COVID-19
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 1,277
- Enrollment target
NCT04568122: Completed NA study, sponsored by Stanford University.
NCT04568122 is a NA study that has completed, run by Stanford University. The registered enrollment target is 1,277 participants, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04568122, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,277 participants
- Enrollment target
Study Summary
The aim of the study is to demonstrate the feasibility and validity of a saliva based home surveillance monitoring test for SARS-CoV-2 infection. Participants will be asked to carry out as many tests as are included in the bag they are provided, on a daily basis until they are used up.
Primary Outcome
Feasibility Outcome. Discrepancy in interpretation of colormetric readout by participant versus by technician via photo. Passed test = void of manufacturing or user error.
Interventions
- DEVICE Saliva test kit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,277 participants |
| Start Date | 2020-11-20 |
| Est. Completion | 2022-12-10 |
| Phase | NA |
What the finished NCT04568122 record still lists
NCT04568122 is an interventional study that assigns participants to a tested intervention. Its 1,277 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Saliva test kit is the first listed.
NCT04568122 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04568122 about?
NCT04568122 is a clinical study titled "Rapid Turnaround, Home-based Saliva Testing for COVID-19". The aim of the study is to demonstrate the feasibility and validity of a saliva based home surveillance monitoring test for SARS-CoV-2 infection. Participants will be asked to carry out as many tests as are included in the bag they are provided, on a daily basis until they are used up.
What is the current status of trial NCT04568122?
This trial is currently completed. It is a NA study. The enrollment target is 1,277 participants. The study started on 2020-11-20. Estimated completion is 2022-12-10.
What interventions are being tested in trial NCT04568122?
The interventions under investigation include: Saliva test kit (DEVICE).
Who is sponsoring clinical trial NCT04568122?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04568122's enrollment target sits among peer trials
1,277 78th of 2000 higher than 1,923 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07001800 · 1,276 participants · Phase 2
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
- NCT07225504 · 1,275 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- NCT03970447 · 1,280 participants · Phase 2
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- NCT06468228 · 1,280 participants · Phase 3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI